Gaps, Obstacles, and Opportunities in Rheumatic Heart Disease Research: Where Are We Now?

doi:10.1016/j.jacadv.2023.100293

Editorial

. 2023 Apr 12;2(3):100293.

doi: 10.1016/j.jacadv.2023.100293. eCollection 2023 May.

Gaps, Obstacles, and Opportunities in Rheumatic Heart Disease Research: Where Are We Now?

Christopher S Yilgwan¹, Nentawe Gurumdimma¹, Ralf Martz Sulague², Jacques Kpodonu³

Affiliations

¹ West African Center of Emerging Infectious Diseases, University of Jos, Jos, Nigeria.
² Graduate School of Arts and Sciences, Georgetown University, Washington, District of Columbia, USA.
³ Division of Cardiac Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

PMID: 38939587
PMCID: PMC11198271
DOI: 10.1016/j.jacadv.2023.100293

Editorial

Gaps, Obstacles, and Opportunities in Rheumatic Heart Disease Research: Where Are We Now?

Christopher S Yilgwan et al. JACC Adv. 2023.

. 2023 Apr 12;2(3):100293.

doi: 10.1016/j.jacadv.2023.100293. eCollection 2023 May.

Authors

Christopher S Yilgwan¹, Nentawe Gurumdimma¹, Ralf Martz Sulague², Jacques Kpodonu³

Affiliations

¹ West African Center of Emerging Infectious Diseases, University of Jos, Jos, Nigeria.
² Graduate School of Arts and Sciences, Georgetown University, Washington, District of Columbia, USA.
³ Division of Cardiac Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

PMID: 38939587
PMCID: PMC11198271
DOI: 10.1016/j.jacadv.2023.100293

No abstract available

Keywords: LMIC; artificial intelligence; rheumatic heart disease; technology.

PubMed Disclaimer

Conflict of interest statement

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Cited by

Polymeric Heart Valves: Addressing Global Gaps in Rheumatic Heart Disease Care?
Vervoort D, Deng MX, Kpodonu J. Vervoort D, et al. JACC Adv. 2025 Jun;4(6 Pt 1):101761. doi: 10.1016/j.jacadv.2025.101761. Epub 2025 May 1. JACC Adv. 2025. PMID: 40315566 Free PMC article. No abstract available.

References

1. Watkins D.A., Johnson C.O., Colquhoun S.M., et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713–722. doi: 10.1056/NEJMoa1603693. - DOI - PubMed
1. Irlam J., Mayosi B.M., Engel M., Gaziano T.A. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2013;6(3):343–351. doi: 10.1161/CIRCOUTCOMES.111.000032. - DOI - PubMed
1. Pearce S., Bowen A.C., Engel M.E., de la Lande M., Barth D.D. The incidence of sore throat and group A streptococcal pharyngitis in children at high risk of developing acute rheumatic fever: a systematic review and meta-analysis. PLoS One. 2020;15(11) doi: 10.1371/journal.pone.0242107. - DOI - PMC - PubMed
1. WHO Study Group on Rheumatic Fever and Rheumatic Heart Disease (2001: Geneva, Switzerland) & World Health Organization. (2004) Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation, Geneva, 20 October - 1 November 2001. World Health Organization. https://apps.who.int/iris/handle/10665/42898 Accessed March 2023.
1. WHO Cardiovascular Diseases Unit and Principal Investigators WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). WHO Cardiovascular Diseases Unit and Principal Investigators. Bull World Health Organ. 1992;70(2):213–218. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Watkins D.A., Johnson C.O., Colquhoun S.M., et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713–722. doi: 10.1056/NEJMoa1603693. - DOI - PubMed

[2] Watkins D.A., Johnson C.O., Colquhoun S.M., et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713–722. doi: 10.1056/NEJMoa1603693. - DOI - PubMed

[3] Irlam J., Mayosi B.M., Engel M., Gaziano T.A. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2013;6(3):343–351. doi: 10.1161/CIRCOUTCOMES.111.000032. - DOI - PubMed

[4] Irlam J., Mayosi B.M., Engel M., Gaziano T.A. Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2013;6(3):343–351. doi: 10.1161/CIRCOUTCOMES.111.000032. - DOI - PubMed

[5] Pearce S., Bowen A.C., Engel M.E., de la Lande M., Barth D.D. The incidence of sore throat and group A streptococcal pharyngitis in children at high risk of developing acute rheumatic fever: a systematic review and meta-analysis. PLoS One. 2020;15(11) doi: 10.1371/journal.pone.0242107. - DOI - PMC - PubMed

[6] Pearce S., Bowen A.C., Engel M.E., de la Lande M., Barth D.D. The incidence of sore throat and group A streptococcal pharyngitis in children at high risk of developing acute rheumatic fever: a systematic review and meta-analysis. PLoS One. 2020;15(11) doi: 10.1371/journal.pone.0242107. - DOI - PMC - PubMed

[7] WHO Study Group on Rheumatic Fever and Rheumatic Heart Disease (2001: Geneva, Switzerland) & World Health Organization. (2004) Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation, Geneva, 20 October - 1 November 2001. World Health Organization. https://apps.who.int/iris/handle/10665/42898 Accessed March 2023.

[8] WHO Study Group on Rheumatic Fever and Rheumatic Heart Disease (2001: Geneva, Switzerland) & World Health Organization. (2004) Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation, Geneva, 20 October - 1 November 2001. World Health Organization. https://apps.who.int/iris/handle/10665/42898 Accessed March 2023.

[9] WHO Cardiovascular Diseases Unit and Principal Investigators WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). WHO Cardiovascular Diseases Unit and Principal Investigators. Bull World Health Organ. 1992;70(2):213–218. - PMC - PubMed

[10] WHO Cardiovascular Diseases Unit and Principal Investigators WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). WHO Cardiovascular Diseases Unit and Principal Investigators. Bull World Health Organ. 1992;70(2):213–218. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gaps, Obstacles, and Opportunities in Rheumatic Heart Disease Research: Where Are We Now?

Affiliations

Gaps, Obstacles, and Opportunities in Rheumatic Heart Disease Research: Where Are We Now?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources